Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of Nintedanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 4/20 | 0.52 |
| ▸ | FGFR1 known ✓ | P11362 | 4/20 | 0.52 |
| ▸ | KDR known ✓ | P35968 | 4/20 | 0.52 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 0.52 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.52 |
| ▸ | FGFR2 known ✓ | P21802 | 2/20 | 0.52 |
| ▸ | FGFR4 known ✓ | P22455 | 2/20 | 0.52 |
| ▸ | FGFR3 known ✓ | P22607 | 2/20 | 0.52 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.52 |
| ▸ | MELK | Q14680 | 9/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.51 |
| ▸ | NUAK1 | O60285 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nintedanib SCHEMBL431006 | 1.00 | AAK1 (0.59) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL1535871 | 1.00 | AAK1 (0.59) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL431007 | 1.00 | AAK1 (0.59) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL2365685 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL2365677 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL4262457 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL2366107 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL2376199 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL2376201 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL2366115 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9375 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4746852-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2026-05-27 | — | — | EP | claimed |
| US-20260137626-A1 | Pharmaceutical Formulation | CIPLA LTD (IN) | 2026-05-21 | — | — | US | claimed |
| US-12629352-B2 | Methods and uses for apelin receptor agonists | RESEARCH TRIANGLE INSTITUTE (US) | 2026-05-19 | — | — | US | claimed |
| US-12630624-B2 | Anti-IL-27 antibodies and uses thereof | Surface Oncology, LLC (US) | 2026-05-19 | — | — | US | claimed |
| CN-122055366-A | GCN2 and PERK kinase modulators and methods of use thereof | 德西费拉制药有限责任公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026102161-A1 | METHODS OF TREATING OVARIAN AND PANCREATIC CANCER | CONCARLO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| CN-122005592-A | Pharmaceutical composition for inhibiting tumor drug resistance and application thereof | 浙江迈镝生物科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| WO-2022028917-A2 | METHODS FOR THE DETERMINATION OF THE PREDISPOSITION FOR A SEVERE OR CRITICAL COURSE OF A COVID-19-DISEASE FROM A MILD OR MODERATE COURSE OF A COVID-19-DISEASE IN A SUBJECT | SCIOMICS GMBH (DE) | 2022-02-10 | — | — | WO | claimed |
| WO-2022026922-A2 | METHODS FOR TREATING EXACERBATIONS OF INFLAMMATORY RESPIRATORY DISEASES | GENENTECH, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2022026510-A1 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | SEAGEN INC. (US) | 2022-02-03 | — | — | WO | claimed |
| US-20220031708-A1 | METHOD FOR TREATING IDIOPATHIC PULMONARY FIBROSIS | NUMEDII, INC. | 2022-02-03 | — | — | US | claimed |
| CN-113993898-A | Human antibodies that bind RET and methods of use thereof | 瑞泽恩制药公司 | 2022-01-28 | — | — | CN | claimed |
| WO-2022020648-A1 | INHIBITORS OF THE ARTEMIN PATHWAY FOR TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2022-01-27 | — | — | WO | claimed |
| US-20220024777-A1 | NOVEL AMORPHOUS ACTIVE PHARMACEUTICAL INGREDIENTS COMPRISING SUBSTANTIALLY AMORPHOUS MESOPOROUS MAGNESIUM CARBONATE | DISRUPTIVE PHARMA AB (SE) | 2022-01-27 | — | — | US | claimed |
| US-20220025465-A1 | SYSTEMS AND METHODS FOR CHARACTERIZING AND TREATING CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2022-01-27 | — | — | US | claimed |
| US-20220023213-A1 | NANOCRYSTALLINE EYE DROP, PREPARATION METHOD AND USE THEREOF | CHENGDU RUIMU PHARMACEUTICALS CO., LTD. (CN) | 2022-01-27 | — | — | US | claimed |
| WO-2022020720-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TCR2 Therapeutics Inc. (US) | 2022-01-27 | — | — | WO | claimed |